Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

ABSTRACT: Interventions: S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622216 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR